The Off-Target Cardioprotective Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors: An Overview

Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a novel class of glucose-lowering drugs, have revolutionized the management of heart failure with reduced and preserved ejection fraction, regardless of the presence of diabetes, and are currently incorporated in the heart failure guidelines. While...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2024-07, Vol.25 (14), p.7711
Main Authors: Ionică, Loredana N, Lința, Adina V, Bătrîn, Alina D, Hâncu, Iasmina M, Lolescu, Bogdan M, Dănilă, Maria D, Petrescu, Lucian, Mozoș, Ioana M, Sturza, Adrian, Muntean, Danina M
Format: Article
Language:English
Subjects:
Animals
Antidiabetics
Blood pressure
Cardiotonic Agents - pharmacology
Cardiotonic Agents - therapeutic use
Diabetes
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - metabolism
Drugs
Glucose
Heart failure
Heart Failure - drug therapy
Heart Failure - metabolism
Hospitalization
Humans
Hypotheses
Kidney diseases
Metabolism
Older people
Pharmaceutical industry
Signal transduction
Sodium
Sodium-Glucose Transporter 2 Inhibitors - pharmacology
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a novel class of glucose-lowering drugs, have revolutionized the management of heart failure with reduced and preserved ejection fraction, regardless of the presence of diabetes, and are currently incorporated in the heart failure guidelines. While these drugs have consistently demonstrated their ability to decrease heart failure hospitalizations in several landmark clinical trials, their cardioprotective effects are far from having been completely elucidated. In the past decade, a growing body of experimental research has sought to address the molecular and cellular mechanisms of SGLT2i in order to provide a better understanding of the off-target acute and chronic cardiac benefits, beyond the on-target renal effect responsible for blood glucose reduction. The present narrative review addresses the direct cardioprotective effects of SGLT2i, delving into the off-target mechanisms of the drugs currently approved for heart failure therapy, and provides insights into future perspectives.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms25147711